Company patents
New England Biolabs, Inc.
New England Biolabs, Inc. maintains a strong focus on Genetic & Microbiological Assays, representing 72.7% of its portfolio, yet the most surprising shift is the rapid emergence of Fermentation & Biosynthesis, which saw a remarkable 250.0% YoY growth in 2025, indicating a significant new strategic direction despite a partial decline so far in 2026. Concurrently, the company appears to be shifting away from Peptides & Proteins and Pharmaceutical Preparations, both experiencing a 100.0% YoY decline in patenting activity so far in 2026.
Patent Trend by Technology Area
Yearly patent publications since 2023
Product themes
Product-level themes inferred from filings since 2023, with category chips showing where each theme appears. Select a theme to filter the patents below.
77 US filings (since 2023) · 6 categories · 10 themes
Methods and reagents designed to improve the specificity, efficiency, or yield of nucleic acid capture, ligation, amplification, or library preparation steps, particularly for sequencing applications or quantitative analysis.
Assays leveraging CRISPR-Cas systems (e.g., Cas12, Cas13) for highly specific and sensitive detection of target nucleic acids, often involving collateral cleavage activity or reporter molecules.
Therapeutic strategies employing nucleic acids (DNA, RNA, oligonucleotides) to modulate gene expression, deliver genetic material, or interfere with disease-causing pathways. Includes gene therapy using viral vectors.
Methods and compositions for identifying, quantifying, or characterizing specific biological molecules (e.g., nucleic acids, proteins, metabolites, antibodies) or microbial species, often for diagnostic, prognostic, or quality control applications.
Methods and kits for amplifying nucleic acids at a constant temperature, enabling faster results and point-of-care applications, often used for pathogen or contamination detection.
Identification and measurement of specific nucleic acid sequences (DNA, RNA), their expression levels, or epigenetic modifications (e.g., methylation) as indicators for disease presence, progression, risk, or treatment response.
Development of therapeutic approaches involving the genetic modification of cells (e.g., T cells, stem cells, macrophages) or the use of viral/non-viral vectors to deliver genetic material for disease treatment.
Modification of protein or peptide sequences, structures, or post-translational modifications (e.g., glycosylation, lipidation) to enhance their stability, solubility, delivery, or therapeutic efficacy.
Self-contained or modular devices designed to automate and integrate multiple steps of molecular diagnostic assays, from sample preparation to result interpretation, often for point-of-care or high-throughput applications.
Methods and systems for the efficient and scalable production, purification, and formulation of proteins and peptides, including fermentation, chromatography, and cell-based expression systems.
Patents
Showing 1-10 of 151